Tradestie Institutional Equity Comparison Engine

RLMD vs VIVS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RLMD Overall Edge

RLMD Captures Institutional Edge (3โ€“0 Pillars ยท 6โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Relmada Therapeutics, Inc. Common Stock (RLMD) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, RLMD trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus VIVS at N/M Forward P/E and -10117.0% operating margin (-51.4% YoY). In options structure, RLMD sits in BREAKDOWN (36th %ile IV; Dealer Gamma Walls on Pro) against VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
RLMD N/M vs VIVS N/M Fwd P/E
Growth & Margin Winner RLMD
Op Margin 0.0% vs -10117.0% ยท YoY +0.0% vs -51.4%
Momentum & Technical Winner RLMD
1Y -27.2% vs -87.0% ยท 52W Pos 5% vs 5%
Options & Structure Winner RLMD
BREAKDOWN (36th %ile IV) vs BREAKDOWN (N/A IV)
RLMD NASDAQ
Relmada Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.11
+8.93% 1D
Market Cap $318.5M
1M Return -3.12%
1Y Return -27.17%
Forward P/E N/M
Unified AI Score
45.5 / 100 HOLD
Tech 32.0 Fund 54.0 Flow 68.0 Mom 54.0
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
1M Return +64.69%
1Y Return -86.99%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RLMD -27.17% VIVS -86.99% Spread: +59.82 pp (RLMD Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period RLMD Revenue VIVS Revenue RLMD Op. Margin VIVS Op. Margin Margin Edge
FY2018 N/A $0M N/A -766.3% VIVS
FY2019 N/A $0M N/A -882.4% VIVS
FY2020 N/A $0M N/A -977.9% VIVS
FY2022 N/A $0M N/A -765.3% VIVS
FY2023 N/A $0M N/A -4792.2% VIVS
FY2024 N/A $0M N/A -13840.4% VIVS
FY2025 N/A $0M N/A -8761.1% VIVS
FY2026 N/A $0M N/A -8768.7% VIVS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RLMD (6) vs VIVS (0)
Institutional Metric RLMD VIVS Criterion Row Winner
Market Capitalization Scale $318.5M $2.4M Larger Scale RLMD
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -51.4% Higher Growth RLMD
Operating Margin (TTM) Profitability 0.0% -10117.0% Higher Margin RLMD
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -64.7% -343.1% Higher ROE RLMD
52-Week Range Position Momentum 5% ($3โ€“$8) 5% ($0โ€“$3) Stronger Trend Tie
Beta / 30D Volatility Risk Regime 1.56ฮฒ ยท 109% Vol 0.83ฮฒ ยท 480% Vol Lower Realized Risk RLMD
Unified Institutional Score Composite Signal 45.5 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite RLMD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RLMD vs VIVS Buy Guide
RLMD BREAKDOWN
137d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 36th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RLMD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VIVS BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live VIVS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RLMD nor VIVS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.